AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7551780 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil mixed with barium preparation
Number of subjects: 141
Study 7551780 — intervention group
Group type: COMPARATOR
Intervention: Standard barium suspension
Number of subjects: 141
Study 2181841 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (275 +/- 29 mg)
Number of subjects: 12
Study 2181841 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 12
Study 2181841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 37351 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol exposure in utero
Number of subjects: 308
Study 37351 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 308
Study 37351 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol exposure in utero with testicular hypoplasia
Number of subjects: 308
Study 37351 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure with testicular hypoplasia
Number of subjects: 308
Study 31837008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial radiotherapy (CRT)
Number of subjects: 176
Study 31837008 — intervention group
Group type: COMPARATOR
Intervention: No cranial radiotherapy (No CRT)
Number of subjects: 176
Study 31138136 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol (10 μg per day)
Number of subjects: 22
Study 31138136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28540506 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue ALN
Number of subjects: 27
Study 28540506 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue ALN
Number of subjects: 27
Study 28540506 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 27
Study 25759183 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-Time Continuous Glucose Monitoring (CGM)
Number of subjects: 160
Study 25759183 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study 23313985 — intervention group
Group type: EXPERIMENTAL
Intervention: Single muscle reinnervation
Number of subjects: 40
Study 23313985 — intervention group
Group type: EXPERIMENTAL
Intervention: Double muscle reinnervation
Number of subjects: 40
Study 21600809 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV educational DVD plus health class
Number of subjects: 626
Study 21600809 — intervention group
Group type: COMPARATOR
Intervention: Health class only
Number of subjects: 626
Study 19397534 — intervention group
Group type: EXPERIMENTAL
Intervention: α-adrenoceptor agonists (specifically midodrine)
Number of subjects: 329
Study 19397534 — intervention group
Group type: EXPERIMENTAL
Intervention: midodrine
Number of subjects: 329
Study 19397534 — intervention group
Group type: EXPERIMENTAL
Intervention: etilefrine
Number of subjects: 329
Study 17388924 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucinol serum 0.3%
Number of subjects: 32
Study 17388924 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 32
Study 10773855 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg Linomide
Number of subjects: 413
Study 10773855 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Linomide
Number of subjects: 413
Study 10773855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 8614083 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic vena caval filters (VCFs) placed in 40 patients
Number of subjects: 120
Study 8614083 — intervention group
Group type: COMPARATOR
Intervention: No intervention (NO VCF group) with 80 patients
Number of subjects: 120
Study 8614083 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic vena caval filters (VCFs)
Number of subjects: 120
Study 1602945 — intervention group
Group type: EXPERIMENTAL
Intervention: Running exercise at 0800, 1200, 1600, and 2000 h (20-min runs at 70% VO2max)
Number of subjects: 12
Study 1602945 — intervention group
Group type: EXPERIMENTAL
Intervention: Running exercise at different times of day
Number of subjects: 12
Study 3970121 — intervention group
Group type: EXPERIMENTAL
Intervention: betaxolol 1%
Number of subjects: 24
Study 3970121 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol 0.5%
Number of subjects: 24
Study 3970121 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 31382171 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3-polyunsaturated fatty acids (O3PUFAs)
Number of subjects: 43
Study 31382171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30138017 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mail boosters containing alcohol norms
Number of subjects: 568
Study 30138017 — intervention group
Group type: COMPARATOR
Intervention: e-mail boosters containing general health information (control)
Number of subjects: 568
Study 27687378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 30
Study 27687378 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study 24385283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 200 mg gemifloxacin
Number of subjects: 17
Study 24385283 — intervention group
Group type: COMPARATOR
Intervention: Oral 320 mg gemifloxacin
Number of subjects: 17
Study 22301066 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 608
Study 22301066 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 608
Study 22301066 — intervention group
Group type: COMPARATOR
Intervention: sham/0.5 mg
Number of subjects: 608
Study 22301066 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 608
Study 20629022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine 100 mg twice daily (Group A)
Number of subjects: 34
Study 20629022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 34
Study 18364130 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician transfer group (n=165)
Number of subjects: 334
Study 18364130 — intervention group
Group type: COMPARATOR
Intervention: Patient transfer group (n=169)
Number of subjects: 334
Study 15701909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran, 36 mg twice daily for 6 months
Number of subjects: 2489
Study 15701909 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/warfarin (subcutaneous enoxaparin, 1 mg/kg twice daily for 5 to 20 days followed by warfarin)
Number of subjects: 2489
Study 15701909 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/warfarin
Number of subjects: 2489
Study 12204728 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive harvesting (Minimal group, n=22)
Number of subjects: 40
Study 12204728 — intervention group
Group type: COMPARATOR
Intervention: Traditional open harvesting (Open group, n=18)
Number of subjects: 40
Study 12204728 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive harvesting (Minimal group)
Number of subjects: 40
Study 10450299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 83
Study 10450299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet
Number of subjects: 83
Study 10450299 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 83
Study 8949696 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflolux II
Number of subjects: 94
Study 8949696 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoCue
Number of subjects: 94
Study 8949696 — intervention group
Group type: COMPARATOR
Intervention: GOM (Roche Ultimate glucose oxidase method)
Number of subjects: 94
Study 2019751 — intervention group
Group type: EXPERIMENTAL
Intervention: Avian-human (ah) influenza A/Kawasaki/9/86 reassortant vaccine, 100 HID50
Number of subjects: 122
Study 2019751 — intervention group
Group type: COMPARATOR
Intervention: Cold-adapted (ca) influenza A/Kawasaki/9/86 reassortant vaccine
Number of subjects: 122
Study 2019751 — intervention group
Group type: EXPERIMENTAL
Intervention: Avian-human (ah) influenza A/Kawasaki/9/86 reassortant vaccine
Number of subjects: 122
Study 31693564 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdrop blood transfusion set at 10 mL/h
Number of subjects: 20
Study 31693564 — intervention group
Group type: COMPARATOR
Intervention: Macrodrop blood transfusion set at 10 mL/h
Number of subjects: 20
Study 31693564 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdrop blood transfusion set at 100 mL/h
Number of subjects: 20
Study 31693564 — intervention group
Group type: COMPARATOR
Intervention: Macrodrop blood transfusion set at 100 mL/h
Number of subjects: 20
Study 28162990 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric eConsults (Treatment group)
Number of subjects: 0
Study 28162990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27422584 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) with multicatheter brachytherapy (32.0Gy/8 fractions or 30.1Gy/7 fractions or 50Gy/0.60‐0.80Gy per pulse)
Number of subjects: 1186
Study 27422584 — intervention group
Group type: COMPARATOR
Intervention: External Beam Whole Breast Irradiation (WBI) with 50Gy and a boost of 10Gy
Number of subjects: 1186
Study 24623069 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection of returned empty gel applicators
Number of subjects: 838
Study 24623069 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of adherence
Number of subjects: 838
Study 22884754 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 52
Study 22884754 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 52
Study 22884754 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 52
Study 22884754 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study 19875477 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 1605
Study 19875477 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 1605
Study 19875477 — intervention group
Group type: EXPERIMENTAL
Intervention: glyburide
Number of subjects: 1605
Study 19208978 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening of all HIV-infected persons for tuberculosis and vice-versa
Number of subjects: 9200000
Study 19208978 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer diagnostic tests for TB
Number of subjects: 9200000
Study 19208978 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of HIV-TB co-infection
Number of subjects: 9200000
Study 16291408 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 1 or 2 mg/kg SC weekly for 12 weeks
Number of subjects: 2335
Study 16291408 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 2335
Study 16291408 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab extended therapy (up to 24 weeks)
Number of subjects: 2335
Study 16291408 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab continuous therapy (up to 108 weeks)
Number of subjects: 2335
Study 12734155 — intervention group
Group type: EXPERIMENTAL
Intervention: s-ketamine 1 mg.kg(‐1) and midazolam 0.2 mg.kg(‐1) (Group K1)
Number of subjects: 90
Study 12734155 — intervention group
Group type: EXPERIMENTAL
Intervention: s-ketamine 2 mg.kg(‐1) and midazolam 0.2 mg.kg(‐1) (Group K2)
Number of subjects: 90
Study 12734155 — intervention group
Group type: COMPARATOR
Intervention: midazolam 0.2 mg.kg(‐1) (Group M)
Number of subjects: 90
Study 10581142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone 125 mg per hour (total 3 g)
Number of subjects: 100
Study 10581142 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 100
Study 10581142 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone after crossover from placebo
Number of subjects: 100
Study 10581142 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone vs placebo after 8 h
Number of subjects: 100
Study 8564104 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges (DBPCFC) with chest symptoms
Number of subjects: 26
Study 8564104 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges (DBPCFC) without chest symptoms
Number of subjects: 26
Study 8564104 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative double-blind, placebo-controlled food challenges (DBPCFC)
Number of subjects: 26
Study 8564104 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine inhalation challenges (MIC)
Number of subjects: 26
Study 1826960 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanidazole (Eta) plus radiotherapy
Number of subjects: 330
Study 1826960 — intervention group
Group type: COMPARATOR
Intervention: Control (radiotherapy only)
Number of subjects: 330
Study 6124473 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (0.4 g b.i.d.)
Number of subjects: 78
Study 6124473 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (1.5 g b.i.d.)
Number of subjects: 78
Study 30522925 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous perfusion assist system (VPAS)
Number of subjects: 102
Study 30522925 — intervention group
Group type: COMPARATOR
Intervention: Limb elevation
Number of subjects: 102
Study 28798201 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 40
Study 25239849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (VD3) supplementation (200,000 IU IM quarterly) and daily oral calcium (Ca) for 12 months (Group D)
Number of subjects: 15
Study 25239849 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 15
Study 23663206 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine/prilocaine
Number of subjects: 15
Study 21303366 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure addressing common blood donor concerns and suggesting specific coping strategies
Number of subjects: 100
Study 21303366 — intervention group
Group type: EXPERIMENTAL
Intervention: Video addressing blood donor concerns and illustrating coping techniques
Number of subjects: 100
Study 21303366 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of brochure and video
Number of subjects: 100
Study 21303366 — intervention group
Group type: COMPARATOR
Intervention: Control brochure on healthy eating and exercise
Number of subjects: 100
Study 19196529 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamorelin (25 mg daily)
Number of subjects: 32
Study 19196529 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamorelin (50 mg daily)
Number of subjects: 32
Study 19196529 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamorelin (75 mg daily)
Number of subjects: 32
Study 19196529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17002661 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration
Number of subjects: 638
Study 17002661 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-clopidogrel response to ADP
Number of subjects: 638
Study 16330592 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotaped interview (testimony method)
Number of subjects: 24
Study 16330592 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 11933550 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (beta-blocker)
Number of subjects: 0
Study 11933550 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0
Study 9689700 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatic resection (TURP)
Number of subjects: 70
Study 9689700 — intervention group
Group type: COMPARATOR
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 70
Study 8154413 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (M) treatment for 72 hours, supplemented with three intraperitoneal doses over the first 24 hours.
Number of subjects: 54
Study 8154413 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (M) treatment
Number of subjects: 54
Study 2801447 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol‐300
Number of subjects: 75
Study 2801447 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol‐300
Number of subjects: 75
Study 2801447 — intervention group
Group type: EXPERIMENTAL
Intervention: iothalamate‐60
Number of subjects: 75
Study 1092821 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cutaneous stimulation
Number of subjects: 18
Study 1092821 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure
Number of subjects: 18
Study 30840336 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year gym-based, supervised exercise intervention (150 minutes of aerobic exercise and 2 strength-training sessions each week)
Number of subjects: 121
Study 30840336 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 121
Study 28052211 — intervention group
Group type: EXPERIMENTAL
Intervention: APF-30 (water rinsing after 30 minutes)
Number of subjects: 25
Study 28052211 — intervention group
Group type: EXPERIMENTAL
Intervention: F-CPP-ACP (using CPP-ACP immediately before water rinsing)
Number of subjects: 25
Study 28052211 — intervention group
Group type: EXPERIMENTAL
Intervention: APF-0 (immediate water rinsing)
Number of subjects: 25
Study 28052211 — intervention group
Group type: COMPARATOR
Intervention: No-F (no fluoride therapy)
Number of subjects: 25
Study 28052211 — intervention group
Group type: COMPARATOR
Intervention: CPP-ACP-0 (using CPP-ACP and immediate water rinsing)
Number of subjects: 25
Study 24627449 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 64
Study 23172405 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised by expert (Group A)
Number of subjects: 9
Study 23172405 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised by expert (Group B)
Number of subjects: 9
Study 23172405 — intervention group
Group type: COMPARATOR
Intervention: Order effect of supervision
Number of subjects: 9
Study 21632808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotreatment with pegvisomant (15-30 mg twice a week) and SA (half the usual dosage)
Number of subjects: 18
Study 21632808 — intervention group
Group type: COMPARATOR
Intervention: SA monotherapy (unchanged dosage)
Number of subjects: 18
Study 19559191 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) daily
Number of subjects: 197
Study 19559191 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) plus aspirin (100 mg) daily
Number of subjects: 197
Study 16776751 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide treatment
Number of subjects: 314
Study 15226784 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (9 g/day for 7 days)
Number of subjects: 21
Study 15226784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11235692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower ministernotomy
Number of subjects: 100
Study 11235692 — intervention group
Group type: COMPARATOR
Intervention: Full sternotomy
Number of subjects: 100
Study 10068977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead levels measured in newborns and infants
Number of subjects: 55
Study 10068977 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-d and Zn-PP levels measured in newborns and infants
Number of subjects: 55
Study 10068977 — intervention group
Group type: COMPARATOR
Intervention: Comparison of urban vs rural subjects
Number of subjects: 55
Study 8277768 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone (800 mg twice a day)
Number of subjects: 363
Study 8277768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine with DMSO (500 mg, four times a day)
Number of subjects: 363
Study 8277768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine with allopurinol (50 mg, four times a day)
Number of subjects: 363
Study 8277768 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone (800 mg at bedtime)
Number of subjects: 363
Study 8277768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine with DMSO (500 mg at bedtime)
Number of subjects: 363
Study 8277768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine with allopurinol (50 mg at bedtime)
Number of subjects: 363
Study 2973595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 174
Study 2973595 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime-Amikacin combination
Number of subjects: 174
Study 30016393 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-suspension seat
Number of subjects: 40
Study 30016393 — intervention group
Group type: COMPARATOR
Intervention: Industry-standard air-suspension seat
Number of subjects: 40
Study 28851779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVA) with verteporfin PDT (vPDT)
Number of subjects: 50
Study 28851779 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept (IVA) with sham photodynamic therapy (sPDT)
Number of subjects: 50
Study 26362691 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation and financial incentives
Number of subjects: 352
Study 26362691 — intervention group
Group type: COMPARATOR
Intervention: Enhanced traditional care
Number of subjects: 352
Study 24021498 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg daily
Number of subjects: 60
Study 24021498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24021498 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 60
Study 21527667 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based lactate indexes
Number of subjects: 20
Study 21527667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation-based lactate indexes
Number of subjects: 20
Study 21527667 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based measures in hot condition
Number of subjects: 20
Study 21527667 — intervention group
Group type: EXPERIMENTAL
Intervention: Acclimation effect on blood-based indexes
Number of subjects: 20
Study 21527667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation-based indexes after acclimation
Number of subjects: 20
Study 21527667 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based methods vs ventilation-based methods
Number of subjects: 20